"skipMainNavigation"
Search
Quick Search in Journals
Quick Search anywhere
Advanced Search
Radiology
Menu
Previous
Next
Contrast Media

Evaluation of Neck and Body Metastases to Nodes with Ferumoxtran 10–enhanced MR Imaging: Phase III Safety and Efficacy Study

Published Online:Sep 1 2003https://doi.org/10.1148/radiol.2283020872

Abstract

PURPOSE: To determine the safety and efficacy of ferumoxtran 10–enhanced magnetic resonance (MR) imaging for diagnosis of metastases to lymph nodes and the clinical usefulness of ferumoxtran 10 in nodal staging.

MATERIALS AND METHODS: One hundred fifty-two patients were injected with ferumoxtran 10. Readers independently evaluated precontrast MR images by using node size criteria and subjective assessment of other imaging features. Ferumoxtran 10–enhanced MR images were evaluated alone and paired with precontrast images for comparison. The diagnostic performances of precontrast MR size criteria and postcontrast MR imaging were evaluated with receiver operating characteristic (ROC) analysis. Lymph node signal intensity was correlated with histopathologic findings. MR imaging and histopathologic nodal stages were compared.

RESULTS: Node-level sensitivity, specificity, and accuracy of precontrast MR imaging were 54%, 82%, and 68%, respectively, with node size criterion alone; 91%, 51%, and 71%, respectively, with subjective reader assessment; 85%, 85%, and 85%, respectively, with postcontrast MR imaging alone; and 83%, 77%, and 80%, respectively, with paired pre- and postcontrast MR imaging. Compared with size criteria, subjective reader assessment had higher sensitivity but substantially lower specificity. Areas under the ROC curve for pre- and postcontrast MR imaging were 0.76 and 0.83, respectively. Nonmetastatic nodes had significantly lower signal intensity than metastatic nodes on postcontrast T2-weighted MR images (P < .001). Postcontrast nodal staging was significantly more accurate than precontrast nodal staging (P < .01). Headache, back pain, vasodilatation, and urticaria each occurred in 6% of patients.

CONCLUSION: Ferumoxtran 10–enhanced MR imaging was safe and effective and facilitated improved diagnostic performance. Use of iron oxide–enhanced MR imaging increased the positive predictive value by 20% and the accuracy by 14% compared with reader assessment. Differentiating patients with no nodal metastatic involvement was more reliable with ferumoxtran 10–enhanced MR imaging than with precontrast MR imaging.

© RSNA, 2003

References

  • 1 Varallyay P, Nesbit G, Muldoon LL, et al. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran 10 with a gadolinium chelate in imaging intracranial tumors. AJNR Am J Neuroradiol 2002; 23:510-519.
    Medline Google Scholar
  • 2 Zimmer C, Weissleder R, Poss K, Bogdanova A, Wright SC, Enochs WS. MR imaging of phagocytosis in experimental gliomas. Radiology 1995; 197:533-538.
    Google Scholar
  • 3 Moore A, Marcecos E, Bogdanow AJ, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 2000; 214:568-574.
    Google Scholar
  • 4 Weissleder R, Heautot JF, Schaffer BK, et al. MR lymphography: study of a high-efficiency lymphotrophic agent. Radiology 1994; 191:225-230.
    Google Scholar
  • 5 Weissleder R, Elizondo G, Josephson L, et al. Experimental lymph node metastases: enhanced detection with MR lymphography. Radiology 1989; 171:835-839.
    Google Scholar
  • 6 Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990; 175:494-498.
    Google Scholar
  • 7 Lee AS, Weissleder R, Brady TJ, Wittenberg J. Lymph nodes: microstructural anatomy at MR imaging. Radiology 1991; 178:519-522.
    Google Scholar
  • 8 Guimaraes R, Clement O, Bittoun J, Carnot F, Frija G. MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement. AJR Am J Roentgenol 1994; 162:201-207.
    Medline Google Scholar
  • 9 Hamm B, Taupitz M, Hussmann P, Wagner S, Wolf KJ. MR lymphography with iron oxide particles: dose-response studies and pulse sequence optimization in rabbits. AJR Am J Roentgenol 1992; 158:183-190.
    Medline Google Scholar
  • 10 Vassallo P, Matei C, Heston WD, McLachlan SJ, Koutcher JA, Castellino RA. Characterization of reactive versus tumor-bearing lymph nodes with interstitial magnetic resonance lymphography in an animal model. Invest Radiol 1995; 30:706-711.
    Medline Google Scholar
  • 11 Muhler A, Zhang X, Wang H, Lawaczeck R, Weinmann HJ. Investigation of mechanisms influencing the accumulation of ultrasmall superparamagnetic iron oxide particles in lymph nodes. Invest Radiol 1995; 30:98-103.
    Medline Google Scholar
  • 12 Rety F, Clement O, Siauve N, et al. MR lymphography using iron oxide nanoparticles in rats: pharmacokinetics in the lymphatic system after intravenous injection. J Magn Reson Imaging 2000; 12:734-739.
    Medline Google Scholar
  • 13 Tanoura T, Bernas M, Darkazanli A, et al. MR lymphography with iron oxide compound AMI-227: studies in ferrets with filariasis. AJR Am J Roentgenol 1992; 159:875-881.
    Medline Google Scholar
  • 14 Hudgins PA, Anzai Y, Morris MR, Lucas MA. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. AJNR Am J Neuroradiol 2002; Apr;23(4):649-656.
    Google Scholar
  • 15 Bengele HH, Palmacci S, Rogers J, Jung CW, Crenshaw J, Josephson L. Biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 180549, by different routes of administration. Magn Reson Imaging 1994; 12:433-442.
    Medline Google Scholar
  • 16 McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 1994; 4:301-307.
    Medline Google Scholar
  • 17 Anzai Y, Blackwell KE, Hirschowitz SL, et al. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology 1994; 192:709-715.
    Google Scholar
  • 18 Bellin MF, Roy C, Kinkel K, et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles—initial clinical experience. Radiology 1998; 207:799-808.
    Google Scholar
  • 19 Harisinghani MG, Saini S, Slater GJ, Schnall MD, Rifkin MD. MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (Combidex): preliminary observations. J Magn Reson Imaging 1997; 7:161-163.
    Medline Google Scholar
  • 20 Harisinghani MG, Saini S, Weissleder R, et al. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. AJR Am J Roentgenol 1999; 172:1347-1351.
    Medline Google Scholar
  • 21 Hoffman HT, Quets J, Toshiaki T, et al. Functional magnetic resonance imaging using iron oxide particles in characterizing head and neck adenopathy. Laryngoscope 2000; 110:1425-1430.
    Medline Google Scholar
  • 22 Nguyen BC, Stanford W, Thompson BH, et al. Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma. J Magn Reson Imaging 1999; 10:468-473.
    Medline Google Scholar
  • 23 Pannu HK, Wang KP, Borman TL, Bluemke DA. MR imaging of mediastinal lymph nodes: evaluation using a superparamagnetic contrast agent. J Magn Reson Imaging 2000; 12:899-904.
    Medline Google Scholar
  • 24 Byers RM, El-Naggar AK, Lee YY, et al. Can we detect or predict the presence of occult nodal metastases in patients with squamous carcinoma of the oral tongue? Head Neck 1998; 20:138-144.
    Medline Google Scholar
  • 25 Hosal AS, Carrau RL, Johnson JT, Myers EN. Selective neck dissection in the management of the clinically node-negative neck. Laryngoscope 2000; 110:2037-2040.
    Medline Google Scholar
  • 26 Johnson JT. Selective neck dissection in patients with squamous cell carcinoma of the upper respiratory and digestive tracts: a lack of adequate data. Arch Otolaryngol Head Neck Surg 1998; 124:353.
    Google Scholar
  • 27 van den Brekel MW, Castelijns JA, Snow GB. The size of lymph nodes in the neck on sonograms as a radiologic criterion for metastasis: how reliable is it? AJNR Am J Neuroradiol 1998; 19:695-700.
    Medline Google Scholar
  • 28 Dillon WP. Cervical nodal metastases: another look at size criteria. AJNR Am J Neuroradiol 1998; 19:796-797.
    Google Scholar
  • 29 Curtin HD, Ishwaran H, Mancuso AA, Dalley RW, Caudry DJ, McNeil BJ. Comparison of CT and MR imaging in staging of neck metastases. Radiology 1998; 207:123-130.
    Google Scholar
  • 30 Sigal R, Vogl T, Casselman J, et al. Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall superparamagnetic iron oxide particles (Sinerem MR) results of a phase-III multicenter clinical trial. Eur Radiol 2002; 12:1104-1113.
    Medline Google Scholar
  • 31 Sharma R, Saini S, Ros PR, et al. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran 10: phase II clinical trial data. J Magn Reson Imaging 1999; 9:291-294.
    Medline Google Scholar
  • 32 Ros PR, Freeny PC, Harms SE, et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995; 196:481-488.
    Google Scholar

Article History

Published in print: Sept 2003